Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
PepGen Inc. PEPG
$14.26
+$0.02 (0.14%)
На 18:05, 12 мая 2023
+106.87%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
353399034.00000000
-
week52high
20.00
-
week52low
4.32
-
Revenue
0
-
P/E TTM
-5
-
Beta
0.00000000
-
EPS
-4.29000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 июн 2023 г. в 04:00
Описание компании
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wedbush | Outperform | 31 мая 2022 г. | |
| SVB Leerink | Outperform | 31 мая 2022 г. | |
| Stifel | Buy | 31 мая 2022 г. | |
| B of A Securities | Buy | 31 мая 2022 г. | |
| SVB Leerink | Outperform | Outperform | 10 ноя 2022 г. |
| HC Wainwright & Co. | Buy | 21 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Svenstrup Niels | D | 25629 | 10000 | 19 дек 2022 г. |
| Svenstrup Niels | A | 10000 | 10000 | 19 дек 2022 г. |
| Dable Habib J | A | 22686 | 22686 | 03 окт 2022 г. |
| Mellion Michelle L | A | 100000 | 100000 | 01 июл 2022 г. |
| Flynn James E | A | 476813 | 208333 | 10 мая 2022 г. |
| Flynn James E | A | 268480 | 268480 | 10 мая 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | D | 0 | 646306 | 10 мая 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | D | 0 | 646306 | 10 мая 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 207672 | 207672 | 10 мая 2022 г. |
| RA CAPITAL MANAGEMENT, L.P. | A | 1302600 | 249749 | 10 мая 2022 г. |
Новостная лента
Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going
Zacks Investment Research
31 янв 2023 г. в 10:15
PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing'
Zacks Investment Research
21 ноя 2022 г. в 10:32
PepGen, Inc. (PEPG) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
3 IPO stocks to watch in September: PEPG, PFHC, HNVR
Finbold
06 сент 2022 г. в 03:45
Initial public offerings (IPOs) are often the most common route companies use to hit the public markets and raise money
Biotech Public Offerings at 10-Year Low
GuruFocus
11 июл 2022 г. в 16:56
No matter how you slice it, this has been a poor year for biotechnology stocks. Not only is the SPDR S&P Biotech ETF ( XBI , Financial) down nearly 29% year to date, but biotech initial public offerings have sunk to a 10-year low, according to a report from Evaluate.
It's Time To Nibble On These Two Recent IPOs
MarketBeat
31 мая 2022 г. в 10:10
It's hard to know what to buy and what to sell with market conditions the way they are but it looks like a good time to start nibbling on these two recent IPOs. Bausch + Lomb (NYSE: BLCO) and PepGen (NASDAQ: PEPG) both IPOd in 2022 and have seen their shares plummet in the wake of the offering, not because they are poor companies or bad investments but simply because the market conditions changed.